HIPEC With Interval Cytoreductive Surgery Improves Survival in Ovarian Cancer

In patients with stage III ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery significantly improves centrally assessed recurrence-free and overall survival, according to results of a study now published in the International Journal of Gynecological Cancer. By enhancing the penetration of chemotherapy at the peritoneal surface, HIPEC has been found to improve outcomes in patients with advanced ovarian cancer. However, the effi...
Continue reading

HIPEC With Cytoreductive Surgery Effective in Ovarian Cancer

For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network Open. Of all the gynecologic cancers, ovarian cancer is the most deadly. This may be due in part to the fact that in almost 70% of cases, by the time a patient is first diagnosed with ovarian cancer, it has already spread beyond ...
Continue reading

Olaparib for BRCA-Mutated Ovarian Cancer: Andrés Poveda, MD

Last weekend, in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, Andrés Poveda, MD, presented results of the phase 3 SOLO2/ENGOT Ov-21 trial, reporting that olaparib significantly increased median overall survival compared with placebo in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In this interview with i3 Health, Dr. Poveda, Executive Co-Director of Initia Oncology in Valencia, Spain, discusses the significance of the trial's results...
Continue reading

Olaparib for BRCA-Mutated Relapsed Ovarian Cancer

In patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer, olaparib maintenance therapy significantly increased median overall survival compared with placebo, according to results of the final analysis of the phase 3 SOLO2/ENGOT Ov-21 trial to be presented this coming weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial enrolled 295 patients with BRCA-mutated relapsed ovarian cancer who were previously treated with at least two lin...
Continue reading

Niraparib Approved for Frontline Maintenance: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

The FDA has now expanded the approval of niraparib (Zejula®, GlaxoSmithKline) to include maintenance therapy for adults with metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. This frontline maintenance approval adds to previous approvals for third-line or later maintenance therapy in these cancers regardless of HRD...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.